Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)(Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc))

概要

基本信息

药物类型

灭活疫苗、联合疫苗、预防性疫苗

+ [1]

别名

Boostrix、Refortrix

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

白喉破伤风百日咳

非在研适应症

带状疱疹乳头状瘤病毒感染流感病毒感染+ [1]

原研机构

GSK Plc

在研机构

GlaxoSmithKline GmbH & Co. KG

GSK PlcGlaxoSmithKline LLC

非在研机构-

最高研发阶段批准上市

首次获批日期

德国 (2000-10-03),

白喉破伤风百日咳

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

42

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的临床试验

NCT06494475

/ Not yet recruiting临床2/3期

A Randomised, Observer-Blind Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of a Group B Streptococcus Vaccine (GBS-NN/NN2) When 1 Dose is Administered Concomitantly With the Tdap Vaccine in Healthy-non Pregnant Women 18 to 49 Years of Age Compared to When Each Vaccine is Administered Alone

The main objectives of the study are to demonstrate the non-inferiority of the immune response induced by co administered GBS-NN/NN2 and tetanus, diphtheria, and acellular pertussis (Tdap) compared to the separate administration of GBS-NN/NN2 and Tdap, to evaluate the reactogenicity of GBS NN/NN2 when administered alone or in combination with Tdap, and to evaluate the safety of GBS-NN/NN2 when administered alone or in combination with Tdap in terms of serious adverse events (SAEs) and unsolicited adverse events (AEs).

开始日期2024-12-17

申办/合作机构

Minervax ApS

NCT06015308

/ Recruiting临床2期

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD).
The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis [Tdap]) and Pneumovax 23 (PPSV) vaccines in adult participants with moderate-to-severe AD treated with amlitelimab versus placebo. The study will evaluate the percentage of participants achieving a positive anti-tetanus response at Week 16 (primary endpoint) and a positive anti-pneumococcal response at Week 16 (primary endpoint).
Study details include:
The study duration will be up to 36 weeks (for participants not entering the LTS17367 [RIVER-AD]).
The screening period will be 2 to 4 weeks. The treatment duration will be up to 16 weeks. The post-treatment safety follow-up period will be16 weeks. The number of visits will be up to 7 (or 6 for those entering LTS17367 [RIVER-AD]).

开始日期2023-10-06

申办/合作机构

Sanofi

NCT05543642

/ Active, not recruiting临床4期IIT

The COvid19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)

Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines.
Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.

开始日期2022-10-11

申办/合作机构

Oregon Health & Science University

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

353

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的文献（医药）

2025-02-01·PEDIATRIC INFECTIOUS DISEASE JOURNAL

Heterologous Effects of Pertussis and Influenza Vaccines During Pregnancy on Maternal and Infant Innate Immune Responses: A Pilot Study

Article

作者: Diavatopoulos, Dimitri ; Islam, Khaleda ; Rice, Thomas F. ; Sancho-Shimizu, Vanessa ; Holder, Beth ; Kampmann, Beate

Background::

Research has demonstrated that some vaccines may have effects on the immune system beyond their intended targets. These heterologous effects of vaccination occur through reprogramming of innate immune cells, resulting in enhanced cytokine responses to unrelated pathogens and have been observed most evidently following Bacillus Calmette–Guérin vaccination. Pregnant women in the United Kingdom are offered influenza and acellular pertussis (Tdap) vaccines to protect the mother and infant, respectively, from infection. Little is known about the potential heterologous effects of vaccines given during pregnancy on the maternal and infant immune systems.

Objective::

To investigate heterologous innate immune responses in mothers and infants from pertussis-vaccinated and pertussis/influenza double-vaccinated pregnancies compared with unvaccinated pregnancies, in a pilot cohort.

Methods::

In this pilot study, samples collected as part of 2 maternal immunization studies were utilized. Maternal and cord peripheral blood mononuclear cells (PBMCs) were collected at birth from women who had received both Tdap and influenza vaccination, only the Tdap vaccine or no vaccines during pregnancy. To further investigate the effect of influenza vaccination alone, PBMCs were collected from nonpregnant women before and after seasonal influenza vaccination. PBMCs were incubated with pattern recognition receptor (PRR) ligands, vaccine adjuvants or CRM197 for 24 hours and cytokine responses were quantified in supernatants by enzyme-linked immunosorbent assay.

Results::

PBMC from women who received both Tdap and influenza vaccines had reduced IL-1β, IL-6 and IL-8 cytokine responses to PRR ligand stimulation, compared with those from women who received Tdap alone. Maternal vaccine status during pregnancy did not impact cytokine responses to PRR stimulation in cord PBMCs. Seasonal influenza vaccination did not alter cytokine responses to PRR ligands in nonpregnant women.

Conclusions::

Our pilot study suggests that PBMC from women receiving combined Tdap and influenza vaccination during pregnancy may have reduced in vitro cytokine responses to nonpertussis stimuli. Larger cohorts of mother-infant pairs need to be studied to confirm these findings, study the potential mechanisms and control for potential confounders.

2025-01-01·VACCINE

Structural equation modeling to evaluate the adult vaccine hesitancy scale for vaccines recommended during pregnancy

Article

作者: Yang, Yingwei ; Nuzhath, Tasmiah ; Regan, Annette K ; Couture, Marie-Claude ; Comeau, Jeannette L ; Gu, Ning Yan

INTRODUCTION:

Acceptance of recommended vaccines is lower among pregnant people compared to non-pregnant adults, yet no tool has specifically measured prenatal vaccine hesitancy. We evaluated the performance of an existing adult Vaccine Hesitancy Scale (aVHS) in measuring vaccine hesitancy toward routinely recommended prenatal vaccines.

METHODS:

Between December 2021 and April 2022, we conducted a cross-sectional national online survey with 917 US postpartum adults 18-49 years old who had given birth in the past six months. Vaccine hesitancy was measured using the aVHS, a 10-item scale previously validated among the adult general population. Scores range from 10 to 50, with higher scores indicating greater vaccine hesitancy. Structural equation modeling (SEM) with weighted least squares means and variances adjusted (WLSMV) estimator was used to assess the fit of the aVHS structure. Construct validity was assessed by examining the correlation between the aVHS score and the self-reported receipt of recommended prenatal vaccines.

RESULTS:

SEM indicated acceptable fit (RMSEA: 0.098; CFI: 0.983; TLI: 0.978; SRMR: 0.040) of the data to the two-factor model: (1) lack of vaccine confidence, and (2) perceived vaccine risks. For the paths from the two factors to the vaccine acceptance, lack of vaccine confidence was significantly correlated with influenza vaccine acceptance (β = -0.41, p < 0.001) and COVID-19 vaccine acceptance (β = -0.64, p < 0.001), while perceived vaccine risk was significantly linked with Tdap vaccine acceptance (β = -0.57, p < 0.001) and influenza vaccine acceptance (β = -0.25, p < 0.001). Additionally, pregnant people with higher aVHS scores were less likely to receive recommended prenatal vaccines.

DISCUSSION:

Although the aVHS offered acceptable measurement of prenatal vaccine hesitancy, a scale that measures pregnancy-specific concerns may offer more tailored measurement for this unique population.

2025-01-01·Lancet Global Health

Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda

Article

作者: Gorringe, Andrew ; Amaral, Kyle ; Nakimuli, Annettee ; Taylor, Stephen ; Sadarangani, Manish ; Andrews, Nick ; Hunter, Olivia F ; Abu-Raya, Bahaa ; Musoke, Philippa ; Greenland, Melanie ; Tusubira, Valerie ; Nakabembe, Eve ; Cantrell, Liberty ; Kyohere, Mary ; Heath, Paul T ; Lesne, Elodie ; Dixon, Louisa ; Amone, Alexander ; Sekikubo, Musa ; Mcstraw, Nikki ; Halkerston, Rachel ; Le Doare, Kirsty ; Imede, Esther

BACKGROUND:

Immunisation in pregnancy against pertussis can reduce severe disease in infancy. There are few data on the safety and immunogenicity of vaccines given to pregnant women living with HIV and their infants. We aimed to describe the safety and immunogenicity of a tetanus-diphtheria-acellular pertussis (TdaP) vaccine containing genetically detoxified pertussis toxin given to pregnant women living with HIV and the effect of the vaccine on infant whole-cell pertussis vaccine responses.

METHODS:

We conducted an observer-blind, randomised, phase 2, multicentre, non-inferiority trial evaluating safety and immunogenicity of a vaccine containing genetically detoxified acellular pertussis in pregnant women living with HIV in Uganda. Women aged at least 18 years between 16 weeks and 26 weeks of gestation were randomly assigned to receive the tetanus-diphtheria (Td) vaccine or TdaP vaccine. Stratified block randomisation using blocks of four with a 1:1:1:1 ratio stratified by participant HIV status was used to distribute participants into equal groups (50 participants per group for a total of 200 participants). The intervention was a 0·5 mL single intramuscular dose of TdaP vaccine. Td or TdaP vaccination was randomly assigned to different clinic days using randomisation software. Primary immunogenicity endpoints were anti-pertussis toxin and anti-filamentous haemagglutinin IgG concentrations in infants at delivery and 18 weeks following three doses of a whole-cell pertussis containing vaccine. This study is registered at ClinicalTrials.gov, NCT04589312.

FINDINGS:

Between Oct 28, 2020, and May 21, 2021, 438 pregnant women were screened and 181 were randomly assigned: 90 to TdaP vaccine (40 HIV-positive participants and 50 HIV-negative participants) and 91 to Td vaccine (41 HIV-positive participants and 50 HIV-negative participants). All participants received Td, and 4 weeks later, 177 received either Td or TdaP. 32 serious adverse events occurred, none related to the study vaccine. At delivery, anti-pertussis toxin IgG concentrations for TdaP versus Td were superior in infants who were HIV-exposed but uninfected (geometric mean ratio 9·61, 95% CI 5·21-17·74) and HIV-unexposed infants (21·6, 11·2-41·7). In infants at 18 weeks, anti-pertussis toxin IgG concentrations for TdaP versus Td-vaccinated mothers were significantly lower for both infants who were HIV-exposed but uninfected (0·19, 0·09-0·43) and infants who were not HIV-exposed (0·17, 0·08-0·33). Serum bactericidal antibody generation following whole-cell pertussis vaccination in infants was not affected.

INTERPRETATION:

TdaP was safe and immunogenic in pregnant women living with HIV and their infants. TdaP provided superior anti-pertussis toxin IgG concentrations at delivery. Following routine vaccination with whole-cell pertussis vaccine, infants born to women receiving the TdaP vaccine had lower anti-pertussis toxin IgG concentrations than infants born to women receiving Td. In the absence of a correlate of protection against pertussis disease, the clinical significance of this finding is unclear.

FUNDING:

Medical Research Council Joint Clinical Trials, Canadian Institutes of Health Research, and British Columbia Children's Hospital Research Institute.

20

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的新闻（医药）

2025-02-06

·生物制品圈

2024年全球疫苗市场深度分析报告

一、引言疫苗作为预防和控制传染病的重要手段，其市场需求和销售额一直是全球公共卫生和医药行业关注的焦点。2024年，全球疫苗市场继续保持增长态势，各大药企在不同疫苗领域的竞争也愈发激烈。本文将基于2024年国外疫苗排行榜的数据，对全球疫苗市场的现状和趋势进行深度分析。二、数据概览根据2024年国外疫苗排行榜的数据，我们可以看到以下主要疫苗及其销售额（单位：亿美元）：头部效应显著：前五名疫苗（Gardasil、Prevnar13/20、Shingrix、PPH、流感疫苗）占据市场主导地位，合计销售额超250亿美元，占总榜单的60%以上。新冠疫苗市场收缩：辉瑞的Comirnaty（新冠疫苗）销售额从2021年的367.8亿美元锐减至2024年的53.5亿美元，降幅达85%，反映疫情常态化后需求大幅下降。新兴疫苗崛起：RSV疫苗（如GSK的Arexvy、辉瑞的Abrysvo）和带状疱疹疫苗（Shingrix）增速亮眼，2023年销售额分别达15.5亿和43.6亿美元，成为市场新增长点。三、市场分析 1. HPV疫苗市场 Gardasil（默沙东）在2024年继续领跑HPV疫苗市场，销售额达到85.83亿美元，尽管较2023年的88.86亿美元略有下降，但仍然占据市场主导地位。 Cervarix（葛兰素史克）销售额持续下降，2024年仅为0.90亿美元，显示出其市场竞争力的减弱。2. 肺炎结合疫苗市场 Prevnar13/20（辉瑞）在2024年销售额为64.11亿美元，较2023年的64.40亿美元略有下降，但仍然是市场的主要玩家。 Vaxneuvance（默沙东）销售额稳定在6.65亿美元，显示出其在市场中的稳定地位。3. 带状疱疹疫苗市场 Shingrix（葛兰素史克）在2024年销售额为42.16亿美元，较2023年的43.59亿美元略有下降，但仍然是带状疱疹疫苗市场的领导者。4. 百白破疫苗市场 PPH（赛诺菲）在2024年销售额为28.56亿美元，较2023年的23.33亿美元有显著增长，显示出其市场竞争力的提升。 Boostrix（葛兰素史克）销售额为8.53亿美元，较2023年的7.74亿美元有所增长。5. 流感疫苗市场流感疫苗（赛诺菲）在2024年销售额为26.62亿美元，较2023年的28.76亿美元有所下降。 Fluarix, FluLaval（葛兰素史克）销售额为5.11亿美元，较2023年的6.36亿美元有所下降。6. RSV疫苗市场 Abrysvo（辉瑞）和Arexvy（葛兰素史克）在2024年销售额分别为7.55亿美元和7.40亿美元，显示出RSV疫苗市场的快速增长。7. 新冠疫苗市场 Comirnaty（辉瑞/BioNTech）和Spikevax（Moderna）在2024年销售额分别为53.53亿美元和30.00亿美元，较2023年有显著下降，显示出新冠疫苗市场需求的逐渐减少。四、药企竞争格局葛兰素史克（GSK）产品线最广：共有9款疫苗上榜，覆盖带状疱疹、脑膜炎、流感等多个领域。明星产品：Shingrix（带状疱疹疫苗）2024年销售额42.2亿美元，同比增长32%，成为其最大收入来源。默沙东（MSD）聚焦高价值疫苗：依赖HPV疫苗（Gardasil）和肺炎疫苗（Vaxneuvance），2024年两款产品合计贡献超92亿美元。潜在风险：Cervarix（二价HPV疫苗）销售额持续下滑，2024年仅0.9亿美元，面临被多价疫苗替代的风险。辉瑞（Pfizer）转型压力：新冠疫苗收入锐减，但通过RSV疫苗（Abrysvo）和肺炎疫苗（Prevnar）维持市场份额，2024年合计销售额71.7亿美元。挑战：脑膜炎疫苗（如Nimenrix）销售额未披露，显示部分产品线增长乏力。五、趋势分析 HPV疫苗市场：尽管Gardasil销售额略有下降，但其市场地位依然稳固。Cervarix的市场份额继续缩小，未来可能需要新的产品或策略来提升竞争力。HPV疫苗在亚洲、非洲等地区的普及率提升空间巨大。肺炎结合疫苗市场：Prevnar13/20和Vaxneuvance的销售额相对稳定，未来市场竞争将主要集中在产品创新和价格策略上。带状疱疹疫苗市场：Shingrix的销售额略有下降，但仍然是市场领导者。未来需要关注新的竞争对手和产品。百白破疫苗市场：PPH的销售额显著增长，显示出其市场竞争力的提升。Boostrix的销售额也有所增长，未来市场竞争将更加激烈。流感疫苗市场：销售额有所下降，未来需要关注市场需求的变化和产品创新。 RSV疫苗市场：Abrysvo和Arexvy的销售额显示出RSV疫苗市场的快速增长，未来市场竞争将更加激烈。新冠疫苗市场：销售额显著下降，显示出新冠疫苗市场需求的逐渐减少。未来需要关注新的疫苗研发和市场需求变化。六、结论 2024年全球疫苗市场继续保持增长态势，但不同疫苗领域的市场表现存在显著差异。HPV疫苗、肺炎结合疫苗和带状疱疹疫苗市场表现较为稳定，而流感疫苗和新冠疫苗市场则面临一定的挑战。全球疫苗市场正从“新冠驱动”转向“多元化创新驱动”。企业需平衡成熟产品（如HPV疫苗）与新兴领域（如RSV疫苗）的投入，同时关注技术迭代与新兴市场需求，以在竞争加剧的环境中保持优势。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观，不代表本站立。

疫苗紧急使用授权

2025-01-06

·drugs

U.S. Whooping Cough Cases Surge

MONDAY, Jan. 6, 2025 -- Rates of whooping cough in the U.S. continue to climb, according to data from the US Centers for Disease Control (CDC). Over 32,000 cases reported have been reported as of mid-December -- about six times more than there were at this time last year, and more than there have been since 2014, according to CNN. Whooping cough, also known as pertussis, is a very contagious respiratory illness that spreads through bacteria in the air. It is common in the United States, with frequent outbreaks. Reported cases have been climbing for several months with about a quarter of all cases reported in Illinois, Indiana and other states in the Midwest. Pennsylvania has more reported cases compared to other states. Some states, such as Oregon, ticked a record high number of cases recently. For 2024, Oregon recorded the highest number of whooping cough cases since 1950, a news release stated. Typically, the infection starts with cold-like symptoms before a serious, full-body cough can develop. The name comes from the sound people make as they try to catch their breath between coughs. The coughing can last for several weeks or even months. Cases dropped during the pandemic, but according to the CDC, recent trends suggest that the U.S. is returning to pre-pandemic levels. Whooping cough can be serious for people of all ages, yet children younger than one year old are especially vulnerable because their immune systems are not fully developed. Prevention in the form of vaccination is the best way to protect against whooping cough, the CDC says; the agency recommends that children get the DTaP vaccine and adolescents and adults get the TDaP vaccine. Among children, vaccination rates for this infectious disease have fallen with only about 92% of kindergartners having gotten their DTaP vaccine for the 2023-2024 school year. Antibiotics can treat the infection, but they work best if it’s caught within the first few weeks. If you think you've been exposed to the respiratory illness, ask your doctor about preventive antibiotics. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗

2025-01-06

·drugs

Pertussis Cases Surging in the United States

MONDAY, Jan. 6, 2025 -- Rates of pertussis in the United States are surging, with more than 32,000 cases reported as of mid-December -- about six times more than at this time last year and more than have been reported since 2014 , according to data from the U.S. Centers for Disease Control and Prevention. Reported cases have been climbing for several months, CNN reports. About a quarter of all cases have been reported in Illinois, Indiana, and other states in the Midwest. Pennsylvania has more reported cases compared with other states. Some states, such as Oregon, ticked a record high number of cases recently. For 2024, Oregon recorded the highest number of pertussis cases since 1950, Oregon Public Broadcasting reported. Cases dropped during the pandemic, but, according to the CDC, recent trends suggest that the United States is returning to prepandemic levels. Prevention, in the form of vaccination, is the best way to protect against whooping cough, the CDC says; the agency recommends that children get the DTaP vaccine and adolescents and adults get the Tdap vaccine. Among children, vaccination rates have fallen; only about 92 percent of kindergartners had gotten their DTaP vaccine for the 2023–2024 school year. This is below the 95 percent federal target. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07CA02	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
白喉	德国	GlaxoSmithKline GmbH & Co. KG	2000-10-03
破伤风	德国	GlaxoSmithKline GmbH & Co. KG	2000-10-03
百日咳	德国	GlaxoSmithKline GmbH & Co. KG	2000-10-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
带状疱疹	临床3期	美国	GSK Plc	2014-02-07
脑膜炎球菌感染	临床3期	美国	GSK Plc	2013-01-10
脑膜炎球菌感染	临床3期	多米尼加共和国	GSK Plc	2013-01-10
脑膜炎球菌感染	临床3期	德国	GSK Plc	2013-01-10
流感病毒感染	临床3期	美国	GSK Plc	2006-10-23
乳头状瘤病毒感染	临床3期	美国	GSK Plc	2006-09-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03589768 (CTgov)	临床2期	白喉 \| 艰难梭菌结肠炎 \| 百日咳 ... 更多	399	BOOSTRIX (BOOSTRIX - Maternal)	膚廠蓋壓顧壓鹹窪網醖 = 夢夢構餘餘齋衊網衊夢鏇蓋糧蓋蓋淵積夢糧艱 (製製築遞鏇鹹淵觸膚願, 餘窪衊鏇製遞窪膚積鹹 ~ 鏇遞醖窪鏇鬱獵繭選膚) 更多	-	2023-01-20
				Td (Td - Maternal)	膚廠蓋壓顧壓鹹窪網醖 = 廠遞壓製鬱糧遞鏇觸餘鏇蓋糧蓋蓋淵積夢糧艱 (製製築遞鏇鹹淵觸膚願, 範餘憲蓋廠願壓獵壓築 ~ 鹹顧製膚鏇選鑰蓋範顧) 更多
NCT03311659 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	448	Boostrix	壓顧範餘膚餘膚遞積壓 = 築築夢鏇顧觸網鬱夢選醖觸廠構襯膚憲觸遞壓 (觸夢獵鹽壓願窪廠淵積, 願網築衊鹽糧獵醖製鏇 ~ 壓構鑰鏇鬱糧憲選壓膚) 更多	-	2019-10-23
NCT02377349 (CTgov)	临床4期	白喉 \| 百日咳 \| 破伤风	688	dTpa (dTpa Group - Mother)	顧衊顧醖壓積鏇襯網醖(壓膚艱壓蓋構壓窪鬱窪) = 壓窪齋鹹築觸範鑰構夢襯膚範壓遞觸淵艱鹹鑰 (壓淵網積鑰願觸鑰夢蓋, 繭壓艱淵衊衊鹹醖積壓 ~ 糧齋範憲餘網衊範鹽衊) 更多	-	2019-01-28
				placebo+Boostrix (Control Group - Mother)	顧衊顧醖壓積鏇襯網醖(壓膚艱壓蓋構壓窪鬱窪) = 範憲鏇選窪餘繭簾顧積襯膚範壓遞觸淵艱鹹鑰 (壓淵網積鑰願觸鑰夢蓋, 簾膚觸憲餘簾鏇遞鬱獵 ~ 製襯夢積餘網製廠鑰顧) 更多
NCT00548171 (CTgov)	临床4期	白喉 \| 百日咳 \| 破伤风	203	Boostrix™ (Boostrix I Group)	衊鹹膚觸鬱鬱蓋糧襯齋 = 構衊獵選鏇醖鹹獵範獵鹹獵淵獵觸網壓鬱蓋齋 (獵觸糧窪鏇積築膚製廠, 顧膚範壓鏇網憲遞遞鹹 ~ 獵齋願餘鹽壓鹽襯繭鹽) 更多	-	2019-01-15
				Boostrix™ (Boostrix II Group)	衊鹹膚觸鬱鬱蓋糧襯齋 = 繭壓襯壓觸艱襯餘襯範鹹獵淵獵觸網壓鬱蓋齋 (獵觸糧窪鏇積築膚製廠, 憲鹽醖遞遞憲膚鬱顧繭 ~ 顧憲糧醖醖鏇積繭齋觸) 更多
NCT00385255 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风 ... 更多	1,726	Fluarix®+Boostrix® (Boostrix+Fluarix Group)	顧鏇憲遞廠簾鏇願鹽膚(願壓遞夢網糧製鑰醖艱) = 顧積膚積簾鑰積齋範蓋壓觸簾鑰積餘夢選選鏇 (網觸選遞簾餘壓積艱齋, 鹹鹽齋襯願淵衊觸醖網 ~ 鬱築繭淵鬱構衊願夢窪) 更多	-	2018-09-17
				Fluarix®+Boostrix® (Fluarix Boostrix Group)	顧鏇憲遞廠簾鏇願鹽膚(願壓遞夢網糧製鑰醖艱) = 構艱餘顧醖顧獵鑰艱築壓觸簾鑰積餘夢選選鏇 (網觸選遞簾餘壓積艱齋, 願憲獵選鑰衊襯餘壓鏇 ~ 糧窪夢製繭糧艱壓鑰網) 更多
NCT00346073 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	2,337	Boostrix™ (Boostrix Group)	遞衊觸鏇廠憲齋鏇醖選 = 糧衊顧鏇夢範憲網餘網憲醖鏇餘鹽積顧築壓遞 (製築夢廠鏇製壓範願鹹, 夢遞選鏇艱鑰齋網糧鏇 ~ 範網獵選鏇夢齋窪蓋選) 更多	-	2018-08-07
				ADACEL® (Adacel Group)	遞衊觸鏇廠憲齋鏇醖選 = 構餘選鬱積襯膚鏇窪範憲醖鏇餘鹽積顧築壓遞 (製築夢廠鏇製壓範願鹹, 窪獵淵餘獵鹽獵夢襯壓 ~ 遞積獵壓糧夢範壓遞範) 更多
NCT01755689 (CTgov)	临床3期	脑膜炎球菌感染	1,300	Cervarix®+Meningococcal vaccine GSK134612 (Nimenrix+Cervarix (1,2,7-Month) Group)	選壓觸鏇觸網構範糧鹽(膚襯鏇鑰壓憲艱壓鹽淵) = 憲糧顧淵膚構淵鬱繭齋餘衊觸糧遞願糧廠鑰淵 (簾顧觸艱獵憲範糧衊齋, 鏇鹽網蓋顧網遞窪膚製 ~ 獵窪構壓鏇遞鏇簾夢範) 更多	-	2018-07-03
				Cervarix®+Meningococcal vaccine GSK134612 (Nimenrix+Cervarix (0,1,6-Month) Group)	選壓觸鏇觸網構範糧鹽(膚襯鏇鑰壓憲艱壓鹽淵) = 糧構製衊繭積範齋獵醖餘衊觸糧遞願糧廠鑰淵 (簾顧觸艱獵憲範糧衊齋, 製憲艱鑰齋獵窪蓋鏇窪 ~ 衊餘鹽壓構獵襯蓋鹽構) 更多
NCT01755689 (Pubmed \| Vaccine) 人工标引	临床3期	脑膜炎球菌感染	1,300	MenACWY-TT+human papillomavirus 16/18 AS04-adjuvanted vaccine+tetanus-diphtheria-acellular pertussis vaccine	構餘艱鑰壓壓鑰廠繭構(憲糧繭遞鑰簾獵製糧淵) = No safety concerns were identified 範鏇製網鬱淵構壓簾範 (網觸觸淵築選鬱窪膚膚 ) 更多	积极	2018-06-22
NCT02052596 (CTgov)	临床3期	白喉 \| 带状疱疹 \| 百日咳 ... 更多	935	Herpes Zoster vaccine GSK 1437173A+Boostrix (GSK1437173A Group)	膚鬱製製壓襯膚淵願構 = 網襯齋糧願齋膚觸製淵簾夢構築糧願網範鑰餘 (鹹觸醖膚淵齋網築齋糧, 觸網選窪範積構糧網鑰 ~ 積夢襯蓋鬱願鹽積簾顧) 更多	-	2018-04-24
				Herpes Zoster vaccine GSK 1437173A+Boostrix (Control Group)	顧鑰築鹽範簾廠襯顧繭(醖鏇觸鬱夢醖膚遞鹽製) = 願積鬱憲糧壓觸壓築糧遞繭鑰壓廠鏇選膚夢範 (襯遞鏇糧餘窪積憲齋艱, 夢齋鑰顧觸選餘襯衊觸 ~ 簾範觸範構網鏇鏇艱獵) 更多
NCT01738477 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	165	Boostrix (Boostrix Group 1)	構鹽繭製壓壓鏇廠鑰築 = 夢艱觸顧淵糧顧網醖齋鹽鬱壓鬱鬱糧獵積膚鏇 (顧範觸襯餘鹽觸壓築獵, 衊齋憲積廠憲鏇選願顧 ~ 膚構醖廠鹽壓願範廠膚) 更多	-	2017-12-27
				Boostrix (Boostrix Group 2)	構鹽繭製壓壓鏇廠鑰築 = 獵廠簾蓋簾獵鏇齋夢製鹽鬱壓鬱鬱糧獵積膚鏇 (顧範觸襯餘鹽觸壓築獵, 壓簾壓選憲鑰繭衊鬱壓 ~ 壓觸醖壓鹹鑰鏇構遞壓) 更多